Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 及 獲批精神疾病精準智能診療創新轉化北京市重點實驗室 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司近期與北京大學第六醫院及山東省 精神衛生中心（統稱「合作方」）分別簽訂重要業務合作協議（統稱「業務合作協 議」），共同推進精神健康數字療法產品的研發與商業化。此外，本公司與北京大 學第六醫院、北京大學軟件工程國家工程研究中心聯合申報的「精神疾病精準智 能診療創新轉化北京市重點實驗室」（「實驗室」）已正式獲准組建。 一、與北京大學第六醫院簽訂業務合作協議 1. 聯合研發內容 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 簽訂重要業務合作協議 研究內 ...

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a decline, with MicroPort NeuroTech (02172.HK) dropping over 7% [1] - Nanjing Panda Electronics Co., Ltd. (00553.HK) and BrainCo Inc. (06681.HK) both fell nearly 6% [1] - Xinwei Medical-B (心玮医疗-B) saw a decline of nearly 3% [1]

Group 1: Neuralink and Brain-Computer Interface Stocks - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026, leading to a significant surge in related stocks [1] - Nanjing Panda Electronics (00553) saw a rise of over 44%, while other companies like Xinwei Medical-B (06609), Micron Brain Science (02172), and Brainhole Laser-B (06681) increased by 11.90%, 17%, and 19.8% respectively [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector showed strong performance, with China's innovative drug licensing exceeding $100 billion last year [1] - Companies such as Gilead Sciences-B (01672), Cloudtop New Medicine (01952), and Innovent Biologics (01801) experienced stock increases of 8.85%, 5.65%, and 6.28% respectively [1] Group 3: Robotics and Technology Stocks - Woan Robotics (06600) saw its stock rise by over 27%, with a midday increase of 19.57% as it prepares to launch its first humanoid household robot [1] - The company reported a compound annual growth rate of 49% in revenue over the past three years [1] Group 4: Other Notable Stock Movements - Kuaishou-W (01024) increased by over 9%, with foreign investors optimistic about its revenue outlook for next year [1] - Fuhong Hanlin (02696) rose by 7% after three of its innovative cancer drugs received IND acceptance [1] - Kelun-Biotech (06990) gained over 7% following the approval of its clinical trial application for the new drug ITGB6 ADC SKB105 [2] - The Golden Group (03939) increased by 3.94% due to the successful implementation of key projects at the Solomon Gold Mine [3]

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

Core Viewpoint - The Hong Kong stock market saw a significant rise in brain-computer interface concept stocks, driven by Elon Musk's announcement that his company Neuralink plans to begin large-scale production of brain-computer interface devices in 2026 [1]. Group 1: Stock Performance - Nanjing Panda Electronics Co., Ltd. experienced a surge of over 14%, reaching a latest price of 5.540 with a total market capitalization of 50.63 billion [2]. - Heartway Medical-B saw an increase of 9.80%, with a latest price of 59.950 and a market cap of 22.89 billion [2]. - MicroPort Scientific Corporation rose by 7.43%, with a latest price of 12.140 and a market capitalization of 69.92 billion [2]. - BrainCo Inc. (Brain动极光-B) increased by 3.53%, reaching a price of 7.040 and a total market value of 89.15 billion [2]. - Lenovo Group Limited also saw a rise of 3.35%, with a latest price of 9.870 and a market capitalization of 1,224.347 billion [2].

Group 1 - Baidu Group-SW (09888) proposes to spin off Kunlun Chip for independent listing on the Hong Kong Stock Exchange main board [1] - Dali Group Holdings (01921) subsidiary Dali International Industrial Company has obtained a temporary industrial license issued by MIMR [1] - Guofu Hydrogen Energy (02582) has completed the delivery of a total of 424 sets of vehicle-mounted high-pressure hydrogen supply systems to its customers [1] Group 2 - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for its inhalation powder of Nintedanib [1] - Fantasia Holdings (01777) has entered into a restructuring agreement with Splendid Fortune to sell 409 million shares of Color Life for USD 4.5284 million [1] - China Hongqiao (01378) has made Hongtuo Industrial a wholly-owned subsidiary of Hongchuang Holdings [1] Group 3 - Brainstorm Cell Therapeutics-B (06681) subsidiary has officially signed a cooperation agreement with Beijing Jianguo Medical for a cognitive digital therapy project [1] - Longpan Technology (02465) plans to invest in a lithium iron phosphate production base with an annual capacity of 240,000 tons, with a total investment not exceeding 2 billion yuan [1] - Zhongzheng International (00943) intends to acquire a digital solution company in the beauty industry for HKD 62.5 million, with resumption of trading on January 5 [1] - Kelun-Biotech (06990) has received approval from the National Medical Products Administration for the clinical trial application of its ITGB6 ADC SKB105 new drug [1]

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to advance cognitive digital therapy, focusing on the assessment and training of cognitive functions from January 1, 2026, to December 30, 2026 [1] Group 1 - The collaboration aims to deepen technological exploration and productization in the mental health field, integrating cutting-edge AI algorithms with clinical needs to create more precise and universal digital therapy products [1] - The partnership will contribute to the establishment of industry standards and market normalization, enhancing the company's solution credibility and facilitating nationwide product promotion [2] - The project focuses on enhancing service capabilities in mental health welfare institutions and community settings, significantly expanding the coverage of the company's products and services while creating social benefits and new market growth opportunities [2] Group 2 - The collaboration with Beijing Jianguo Medical strengthens the company's network with national research institutions, accumulating real-world data that will drive algorithm iteration, product optimization, and innovative research and development [2]

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to develop and promote cognitive digital therapy, aiming for standardization and accessibility in the field of cognitive disorders [1][2]. Group 1: Deepening Technical Exploration - The collaboration will enhance technical exploration and productization in mental health by integrating cutting-edge AI algorithms with clinical needs, leading to more precise and universal technology products [1]. Group 2: Establishing Industry Standards - The project will contribute to the establishment of national standards and market normalization, accumulating high-level evidence-based medical data and enhancing the authority of the company's solutions for nationwide promotion [2]. Group 3: Expanding Service Network - The initiative focuses on mental health welfare institutions and community settings, aiming to improve service capabilities for cognitive disorders, thereby increasing market penetration and creating significant social benefits [2]. Group 4: Strengthening Research Collaboration - The partnership with Beijing Jianguo Medical will solidify the company's collaboration network with national research institutions, with real-world data from long-term research cohorts serving as valuable assets for algorithm iteration and product optimization [2].

Core Viewpoint - The collaboration between Brain Dynamics Aurora-B (06681.HK) and Beijing Jianguo Medical Technology aims to standardize and scale digital therapies for cognitive disorders from January 1, 2026, to December 30, 2026 [1] Group 1: Collaboration Details - The partnership will focus on developing a core technical indicator system for cognitive disorder digital therapies, providing evidence-based data and draft texts for national standard establishment [2] - A multi-center pilot program will be implemented in various cities, including Hangzhou, Nanning, Wuhan, and Mudanjiang, targeting to cover 80% of relevant institutions with the "Brain Dynamics Cognitive Function Assessment and Training System" [2] - A long-term research cohort will be established across multiple institutions and regions, with all data jointly owned by the project parties, aimed at informing policy-making, technology upgrades, and standard iterations [2] Group 2: Project Objectives - The project addresses the insufficient service capacity for cognitive disorders within mental health and social welfare systems, aiming to create a replicable and scalable digital therapy application model through national standard formulation and multi-scenario application validation [3] - This collaboration represents a significant step for the company in the implementation and ecosystem development of cognitive disorder digital therapies, following its participation in national science and technology major projects and the establishment of a key laboratory in Beijing [3]